Study guide
8.4 Sterile and Hazardous Compounding under NAPRA Standards
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
8.4 Sterile and Hazardous Compounding under NAPRA Standards
Key Takeaways Explain This Topic AI
NAPRA sterile compounding standards mandate strict ISO cleanroom classifications: ISO Class 5 for the Primary Engineering Control (PEC/Direct Compounding Area), ISO Class 7 for the Cleanroom Buffer Area, and ISO Class 8 (or 7 for hazardous) for the Anteroom.
Non-hazardous sterile compounding requires positive pressure airflow cascading outward from the buffer area to prevent contaminant ingress; hazardous sterile compounding requires negative pressure (-0.01 to -0.03 inches w.g.) and 100% external venting with minimum 30 ACPH.
The mandatory garbing sequence proceeds strictly from dirtiest to cleanest: shoe covers -> hair/head cover -> beard cover -> face mask/eye shield -> hand hygiene (30 sec) -> non-shedding gown -> alcohol rub -> sterile powder-free gloves over gown cuffs.
Default sterile Beyond-Use Dates (BUDs) under NAPRA/USP <797> for low-risk preparations compounded in an ISO 5 PEC within an ISO 7 buffer are: 48 hours at room temperature, 14 days refrigerated (2-8°C), and 45 days frozen (-25°C to -10°C).
Hazardous sterile compounding requires Closed System Drug-Transfer Devices (CSTDs), specialized ASTM D6978 chemotherapy gloves, chemo-rated gowns, and dedicated yellow/black waste management to prevent occupational exposure.
Last updated: August 2026
8.4 Sterile and Hazardous Compounding under NAPRA Standards
Exam Focus: The PEBC Evaluating Examination rigorously assesses the NAPRA Model Standards for Pharmacy Compounding of Sterile and Hazardous Preparations, including ISO air classifications, cleanroom differential pressure cascades, strict aseptic garbing sequences, sterile BUD determinations, media-fill testing, and hazardous drug safety under NIOSH standards.
Cleanroom Architecture and ISO Air Quality Standards
Sterile compounding environments must control particulate matter, airborne microorganisms, and pyrogens to prevent bloodstream and ophthalmic infections. The International Organization for Standardization (ISO 14644-1) classifies air cleanliness based on the maximum allowable concentration of airborne particles ≥ 0.5 μ m \ge 0.5\ \mu\text{m} ≥ 0.5 μ m per cubic meter. +-------------------------------------------------------------------------+
- | CLEANROOM ISO CLASSIFICATION HIERARCHY |
- +-------------------------------------------------------------------------+
- | |
- | [ISO CLASS 5 (Class 100)] |
- | - Max 3,520 particles (>= 0.5 um) / m3 |
- | - Primary Engineering Control (PEC) & Direct Compounding Area (DCA) |
- | - HEPA filter efficiency: 99.97% of particles >= 0.3 um |
- | - Laminar Airflow Workstation (LAFW), Class II BSC, CAI/CACI |
- | | |
- | v |
- | [ISO CLASS 7 (Class 10,000)] |
- | - Max 352,000 particles (>= 0.5 um) / m3 |
- | - Cleanroom Buffer Room (Core compounding suite) |
- | - Minimum 30 Air Changes Per Hour (ACPH) |
- | | |
- | v |
- | [ISO CLASS 8 (Class 100,000)] |
- | - Max 3,520,000 particles (>= 0.5 um) / m3 |
- | - Anteroom (Garbing, hand hygiene, staging for non-hazardous) |
- | - Minimum 20 Air Changes Per Hour (ACPH) |
- | |
- +-------------------------------------------------------------------------+
Cleanroom Zone ISO Classification Max Particles ( ≥ 0.5 μ m / m 3 \ge 0.5\ \mu\text{m}/\text{m}^3 ≥ 0.5 μ m / m 3 ) Minimum ACPH Core Clinical Purpose
Direct Compounding Area (DCA) ISO Class 5 3,520 Unidirectional Direct manipulation of critical sites within PEC exposed to "first air".
Primary Engineering Control (PEC) ISO Class 5 3,520 Unidirectional LAFW, Class II BSC, CAI, or CACI providing laminar HEPA-filtered air.
Buffer Area (Non-Hazardous) ISO Class 7 352,000 ≥ 30 \ge 30 ≥ 30 Enclosed room housing non-hazardous PECs; positive pressure relative to anteroom.
Buffer Area (Hazardous) ISO Class 7 352,000 ≥ 30 \ge 30 ≥ 30 Enclosed room housing hazardous C-PECs; negative pressure relative to anteroom.
Anteroom (Non-Hazardous) ISO Class 8 3,520,000 ≥ 20 \ge 20 ≥ 20 Garbing, hand hygiene, order entry; positive pressure relative to outside.
Anteroom (Hazardous) ISO Class 7 352,000 ≥ 30 \ge 30 ≥ 30 Required ISO 7 to prevent contaminant draw into negative pressure buffer area.
Differential Pressure Cascades: Non-Hazardous vs. Hazardous +-------------------------------------------------------------------------+
- | CLEANROOM PRESSURE CASCADE COMPARISON |
- +-------------------------------------------------------------------------+
- | |
- | NON-HAZARDOUS STERILE (Positive Pressure Outward Cascade): |
- | [General Dispensary] ---> [Anteroom (ISO 8)] ---> [Buffer Area (ISO 7)]
- | (Baseline) (+0.02" w.g.) (+0.05" w.g.)
- | *Air flows OUTWARD from cleanest to dirtiest zone to block microbes. |
- | |
- | HAZARDOUS STERILE (Negative Pressure Inward Containment): |
- | [General Dispensary] <--- [Anteroom (ISO 7)] ---> [Buffer Area (ISO 7)]
- | (Baseline) (+0.02" w.g.) (-0.01 to -0.03" w.g.)
- | *Air flows INWARD to negative buffer to contain toxic drug aerosols. |
- | *C-PEC must be 100% EXTERNALLY VENTED (Class II Type B2 or vented A2). |
- | |
- +-------------------------------------------------------------------------+
- Key Pressure Rules
Non-Hazardous Cleanroom: Maintains a positive pressure differential of + 0.02 to + 0.05 inches of water column +0.02\text{ to }+0.05\text{ inches of water column} + 0.02 to + 0.05 inches of water column ( + 5 to + 12.5 Pa +5\text{ to }+12.5\text{ Pa} + 5 to + 12.5 Pa ) between the buffer room and the anteroom, ensuring air rushes outward when doors are opened.
Hazardous Cleanroom: Maintains a negative pressure differential of − 0.01 to − 0.03 inches of water column -0.01\text{ to }-0.03\text{ inches of water column} − 0.01 to − 0.03 inches of water column ( − 2.5 to − 7.5 Pa -2.5\text{ to }-7.5\text{ Pa} − 2.5 to − 7.5 Pa ) between the hazardous buffer room and the anteroom, ensuring hazardous airborne drug particles cannot escape into general areas. Exhaust air must be 100 % 100\% 100% externally vented through dedicated ductwork to the outside.
Aseptic Garbing Sequence and Hand Hygiene Protocol
NAPRA and USP <797> mandate an exact, non-negotiable sequence of gowning and garbing performed strictly from dirtiest to cleanest in the Anteroom across the designated line of demarcation: +-------------------------------------------------------------------------+
- | MANDATORY GARBING SEQUENCE |
- +-------------------------------------------------------------------------+
- | |
- | [STEP 1: DIRTIEST ZONE - Prior to crossing line of demarcation] |
- | 1. Dedicated cleanroom shoe covers (or dedicated cleanroom shoes) |
- | 2. Head and hair cover (ensure all hair is completely tucked) |
- | 3. Facial beard cover (if applicable) |
- | 4. Face mask and eye shield / safety goggles |
- | |
- | [STEP 2: HAND HYGIENE AT ANTEROOM SINK] |
- | 5. Clean under fingernails with nail pick under warm running water |
- | 6. Wash hands and forearms up to elbows vigorously for >= 30 SECONDS |
- | using antimicrobial soap; dry completely with lint-free wipes |
- | |
- | [STEP 3: CROSS LINE OF DEMARCATION INTO CLEANER ZONE] |
- | 7. Don non-shedding, poly-coated cleanroom gown with snug cuffs |
- | 8. Apply alcohol-based hand rub with persistent activity; allow to dry |
- | |
- | [STEP 4: INSIDE BUFFER AREA PRIOR TO ENTERING ISO 5 PEC] |
- | 9. Don STERILE, powder-free gloves (cuffs pulled over gown sleeves) |
- | 10. Disinfect gloves with sterile 70% Isopropyl Alcohol (IPA) |
- | |
- +-------------------------------------------------------------------------+
- Sterile Beyond-Use Dating (BUD) Risk Categories
Sterile preparation BUDs are determined by the compounding risk level, environmental conditions, and storage temperatures.
Compounding Risk Level Environmental Condition Storage: Controlled Room Temp ( 20 − 25 ∘ C 20-25^\circ\text{C} 20 − 2 5 ∘ C ) Storage: Refrigerated ( 2 − 8 ∘ C 2-8^\circ\text{C} 2 − 8 ∘ C ) Storage: Frozen ( − 25 to − 10 ∘ C -25\text{ to }-10^\circ\text{C} − 25 to − 1 0 ∘ C )
Low Risk ISO 5 PEC in ISO 7 Buffer; ≤ 3 \le 3 ≤ 3 sterile commercial components, ≤ 2 \le 2 ≤ 2 entries per container. 48 hours 14 days 45 days
Medium Risk ISO 5 PEC in ISO 7 Buffer; multiple pooled doses, complex transfers (e.g., TPN, batch fills). 30 hours 9 days 45 days
High Risk Non-sterile starting ingredients or sterile ingredients exposed to worse than ISO 5 for > 1 hr >1\text{ hr} > 1 hr ; terminal sterilization required. 24 hours 3 days 45 days
Segregated Compounding Area (SCA) ISO 5 PEC in unclassified room without ISO 7 buffer/anteroom. 12 hours 24 hours N/A (Do not freeze)
Immediate Use Emergency bedside resuscitation outside cleanroom. 1 hour (Admin must start within 1 hr) 1 hour N/A
Single-Dose Vials (SDVs) versus Multi-Dose Vials (MDVs)
Single-Dose Vials (SDVs): Contain no antimicrobial preservatives.
Punctured in ISO Class 5 air: May be used for up to 6 hours .
Punctured in worse than ISO Class 5 air: Must be used immediately and discarded within 1 hour .
Ampules: Must be discarded immediately after opening; cannot be stored for any duration.
Multi-Dose Vials (MDVs): Contain antimicrobial preservatives (e.g., benzyl alcohol, phenol).
BUD after initial puncture: Maximum 28 days (unless manufacturer specifies a shorter duration).
Quality Assurance, Environmental Monitoring, and Personnel Qualification
To ensure sterility assurance, cleanroom personnel and facilities undergo continuous validation:
Glove Fingertip Sampling: Evaluates personal aseptic technique. Tested initially before compounding (requires 3 consecutive samples yielding 0 CFU ) and annually thereafter (must yield ≤ 3 CFU \le 3\text{ CFU} ≤ 3 CFU ). Both hands are sampled immediately after garbing.
Media-Fill Challenge Testing: Personnel compound a simulated regimen using sterile soybean-casein digest (tryptic soy broth) mimicking their most complex compounding manipulations. Incubated at 20 − 25 ∘ C 20-25^\circ\text{C} 20 − 2 5 ∘ C and 30 − 35 ∘ C 30-35^\circ\text{C} 30 − 3 5 ∘ C for 14 days; any visible microbial turbidity represents failure .
Air and Surface Sampling: Volumetric viable air sampling is conducted every 6 months; surface sampling using contact plates with neutralizing media (lecithin and polysorbate 80) is conducted periodically.
HEPA Filter Recertification: Primary and secondary engineering controls must be certified by an accredited technician every 6 months or whenever equipment is moved or repaired.
Hazardous Drug Handling and Containment (NIOSH & NAPRA/USP <800>)
Hazardous drugs (antineoplastics, cytotoxic agents, teratogens) present occupational carcinogenicity, genotoxicity, and reproductive harm risks:
Closed System Drug-Transfer Devices (CSTDs): Mechanically prohibit the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system. Recommended during compounding and mandatory during bedside nursing administration .
Chemotherapy PPE: Compounding personnel must wear:
Two pairs of ASTM D6978-compliant chemotherapy gloves (outer sterile pair over gown cuff, inner pair under gown cuff; changed every 30 minutes).
Chemotherapy-tested, non-permeable gown (closed back, polyethylene-coated; changed every 2-3 hours or immediately if contaminated).
NIOSH-approved N95 or PAPR respirator (for spill management and aerosol-generating tasks).
Spill and Waste Protocols: Yellow waste containers for trace chemotherapy waste (empty vials, syringes, PPE); black containers for bulk hazardous waste ( > 3 % >3\% > 3% residual drug volume).